Biogen, Inc. to Provide Company Update at Chase H&Q Healthcare Conference in San Francisco

Presentation to be web cast live

Biogen, Inc. (NASDAQ/BGEN) will be presenting a company update at the Chase H&Q; Healthcare Conference in San Francisco.

The presentation will be web cast live for investors at http://www.chasehq.com/events/index.html.

WHO:James C. Mullen, President and Chief Executive Officer of Biogen, Inc.

WHEN:January 9, 2001 at 9:00 a.m. (PST)

WHERE:Chase H&Q; Healthcare Conference
Westin St. Francis Hotel
San Francisco, CA

CONTACT:Rob Jacobson, rob_jacobson@biogen.com, Biogen, Inc.

Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company’s revenues are generated from international sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products ( Prescribing Information ). Biogen’s research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen’s Homepage on the World Wide Web at http://www.biogen.com